iBio, Inc. (AMEX:IBIO) reported the allowance of a Chinese patent on its lichenase fusion protein technology for therapeutic proteins and vaccines. Ibio Inc. (NYSEMKT:IBIO) shares after opening at $0.49 moved to $0.54 on last trade day and at the end of the day closed at $0.511. Company price to sales ratio in past twelve months was calculated as 55.84 and price to cash ratio as 5.88. Ibio Inc. (NYSEMKT:IBIO) showed a positive weekly performance of 8.68%.
bluebird bio, Inc. (NASDAQ:BLUE) a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and orphan diseases, on 27 march announced that the first subject with beta-thalassemia major has been enrolled in its phase 1/2 Northstar Study (HGB-204) in the United States and has undergone infusion with bluebird bio’s LentiGlobin drug product in an autologous hematopoietic stem cell transplantation. Bluebird bio Inc. (NASDAQ:BLUE) shares fell -1.43% in last trading session and ended the day on $19.95. BLUE return on equity ratio is recorded as -32.60% and its return on assets is -13.90%.
Acceleron Pharma Inc. (NASDAQ:XLRN) a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, on 23 April announced that its collaboration partner, Celgene Corporation, presented interim data data demonstrating dose dependent increases in hemoglobin in patients with end stage renal disease (ESRD) on hemodialysis. Acceleron Pharma Inc. (NASDAQ:XLRN) shares moved down -4.70% in last trading session and was closed at $31.85, while trading in range of $30.00 – $35.19. Acceleron Pharma Inc. (NASDAQ:XLRN) year to date (YTD) performance is -19.57%.
Cytokinetics, Inc. (NASDAQ:CYTK) announced that the results from-BENEFIT-ALS will be presented at a Platform Session that is slated to be held at the 66th Annual Meeting of American Academy of Neurology on 26 April 26 – 3 May , 2014 at- Pennsylvania Convention Center in Philadelphia, in PA. Cytokinetics, Inc. (NASDAQ:CYTK) weekly performance is 43.22%. On last trading day company shares ended up $12.99. Cytokinetics, Inc. (NASDAQ:CYTK) distance from 50-day simple moving average (SMA50) is 33.47%. Analysts mean target price for the company is $22.71.
Leave a Reply